| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_546e9ccf59572045315cad7760e24500
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4086331fc5497c7773a76e9f85aac8f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d38fdb9251c0acb0da84ec0e6ab9788
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a933a0dd561e3e50b278738704d5c6e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_72432acf468f47fb01288e684c9322bf |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5052 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate |
2003-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aeca7a159b9472cf001e8289cae61602
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ba07453da51c81a64a230e2a181dada
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ae7bf4cd3cdf089ec7ae9dc09e815c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3d672a44bc339c8f8ee5cae2a9690fc |
| publicationDate |
2003-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03099104-A2 |
| titleOfInvention |
Elisa assay of serum soluble cd22 to assess tumor burden/relapse in subjects with leukemia and lymphoma |
| abstract |
Disclosed herein are methods of using previously unknown soluble forms of CD22 (sCD22) present in the serum of subjects with B-cell leukemias and lymphomas to assess tumor burden in the subjects. Also disclosed are methods of diagnosing or prognosing development or progression of a B-cell lymphoma or leukemia in a subject, including detecting sCD22 in a body fluid sample taken or derived from the subject, for instance serum. |
| priorityDate |
2002-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |